Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-103.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.21 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -24.22% |
| Return on Assets (Trailing 12 Months) | -23.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 28.66 |
| Quick Ratio (Most Recent Fiscal Quarter) | 28.66 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.48 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.90M |
| Free Float | 45.12M |
| Market Capitalization | $2.93B |
| Average Volume (Last 20 Days) | 1.66M |
| Beta (Past 60 Months) | 0.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |